Hard Tech Week Is About Hardware. We Sell the Software.

Hard Tech Week runs Oct. 26-30 across Utah this year, organized by 47G, with the Zero Gravity Summit anchoring it on Oct. 28 and 29. 47G calls the summit its flagship event, and the week around it carries demos, facility tours and showcases at sites across the state.

Neurova Labs is based in Salt Lake City. The week is worth writing about from here, because 47G publishes a definition of hard tech that puts a sharp question to our own category.

47G's definition, and the traits it names

47G describes hard tech as companies built on complex physical hardware and deep scientific breakthroughs. It names four traits: technical complexity, capital intensity, long development cycles and high barriers to entry, and tangible outputs.

That is a clear line and it is drawn around the physical object. Rockets, sensors, propulsion, materials, manufacturing. The traits follow from the object: hardware takes years, costs a great deal before it earns anything, and arrives as a thing you can put on a table.

Where a neurotechnology company sits on that line

Neurotechnology gets filed under hard tech by reflex, because most people meet it as a device. A headset, a cap, an implant, a wearable. The object is the part a buyer can see, so the object becomes the category.

Our own answer is that Neurova Labs sits on the software side of that line, and we say so deliberately. Neurova Labs is a software-access company. It owns the hardware that delivers the program and it sells access to the software running on it. The program itself is content, sequencing, facilitation and measurement, which are the parts that took the work and the parts that change when we improve something.

Two of 47G's four traits still apply to us and two do not. Technical complexity applies, because the program is informed by functional near-infrared spectroscopy imaging and an optional 22-marker RNA gene expression panel run through a CLIA-certified, CAP-accredited laboratory. Long development cycles apply, for the same reason. Capital intensity and tangible outputs describe a hardware business, and a software-access business carries neither in the same way.

None of that makes one model better than the other. It makes them different purchases, and a buyer who does not know which one is in front of them cannot evaluate either.

Software access, and the thing an organization actually buys

An organization buying Neurova Academy is buying a program its own people run. A facilitator from the organization's staff earns certification remotely. A cycle runs five days, with Day 1 as an introduction and four session days after it, one session a day of about 30 minutes, each participant working in about a square meter of floor space in a quiet room the organization already has. No clinician is required on site. The program adds no intake, no diagnosis and no documentation for the host.

Commercially, that structure means the thing being purchased keeps changing after the purchase. A hardware buyer owns the version they bought. A software-access buyer gets what is current, which is the argument for the model and also its obligation: the content has to keep earning the access.

It also means the questions worth asking differ from the ones a hardware buyer asks. Nobody needs to ask us about tooling, unit economics at volume or supply chain. The questions that matter are about the program and the evidence behind it.

Four questions for an investor or a buyer in this category

Is the company selling a device, access to software, or a service delivered by its own staff? Those are three businesses with three cost structures, and the marketing often blurs them.

What exactly does the customer own after the money changes hands, and for how long? A stated hardware lifecycle is a fair answer. No answer is not.

Which claims does the company make about outcomes, and what study sits behind each one? Ask for the participant count and the design in the same breath as the percentage.

Who runs the program on the customer's premises, and what does that person have to be qualified to do? The answer decides whether the thing can scale past the places that already have clinicians.

We publish our own answers to all four. Our claims page carries our full position on what the evidence in this category supports and what it does not, and our measurement page states the limits of the panel. Any figure we publish carries its participant count and its study.

The honest version of our own category claim

Neurova Academy is a facilitator-led general wellness and cognitive training program from Neurova Labs. It is not a medical device, and the regulatory position behind that sentence is on our general wellness page rather than asserted here. We hold observational pilot findings from our own cohorts. We make no claim that the program treats or prevents any condition, and we make no claim to measure cognitive readiness.

A week built around hardware is a good occasion to say plainly which part of a category you occupy. Ours is the software, the program inside it and the measurement around it.

---

Neurova Academy is a general wellness and cognitive training program. It is not a medical device and is not offered to diagnose, treat, cure, or mitigate any disease or condition, including concussion, traumatic brain injury, or CTE. Outcomes described reflect observational pilot findings and individual experience, and are not a prediction of results for anyone else. Individual results vary. Laboratory testing provided by iXpressGenes, a CLIA-certified, CAP-accredited laboratory. References to news reporting, government publications, and published research are for commentary only and do not imply endorsement of Neurova Labs by any federal entity or research institution.

Media contact: Nathaniel Free, chief communications officer, nathaniel.free@neurovalabs.com